Comparative Pharmacology
Head-to-head clinical analysis: MAREZINE versus METOZOLV ODT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAREZINE versus METOZOLV ODT.
MAREZINE vs METOZOLV ODT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Marezine (cyclizine) is a piperazine-derivative histamine H1-receptor antagonist with central anticholinergic and antiemetic activity. It competitively blocks H1 receptors in the vestibular apparatus and the chemoreceptor trigger zone (CTZ), suppressing nausea and vomiting. It also has antimuscarinic effects on the vomiting center.
Selective 5-HT3 receptor antagonist; blocks serotonin action at vagal nerve terminals and in the chemoreceptor trigger zone, inhibiting emetic reflex.
50 mg intramuscularly or intravenously every 4 to 6 hours as needed for motion sickness; 50 mg orally 30 to 60 minutes before travel, then every 4 to 6 hours up to 150 mg/24h.
2.5 mg to 5 mg orally once daily, as disintegrating tablet; may increase to 10 mg if needed
None Documented
None Documented
Terminal elimination half-life is 4-6 hours in adults; prolonged to 8-12 hours in elderly or hepatic impairment
~1.5–2 hours in normal renal function; prolonged to 10–20 hours in severe renal impairment (CrCl <30 mL/min).
Renal: 70-80% as unchanged drug and metabolites; fecal: ~20%; biliary: minor
Renal: ~70% as unchanged drug; biliary/fecal: ~30% as metabolites and unchanged drug.
Category C
Category C
Antiemetic
Antiemetic